The recent promising results with anti-CGRP monoclonal antibodies and previously approved botulinum toxin for the prophylactic treatment of CM prompt us to facilitate the use of evidence-based prophylactic treatment options. This evidence concerns the gene CALCA and cutaneous mastocytosis.